Amgen to acquire Horizon Therapeutics for $28.3 billon
William Fry, working closely with Sullivan & Cromwell LLP, is advising Amgen Inc on its proposed acquisition of Horizon Therapeutics plc.

 

William Fry, working closely with Sullivan & Cromwell LLP, is advising Amgen Inc., one of the world's leading independent biotechnology companies, on its proposed acquisition of Horizon Therapeutics plc, a global biotechnology company headquartered in Dublin, for an enterprise value of $28.3 billion. The all-cash deal, which is subject to shareholder and regulatory approval, is expected to close in the first half of 2023. For more information, please see the Company's release here.

The William Fry cross departmental deal team includes Corporate partners Myra Garrett and Mark Talbot and Corporate senior associate Fiachra Cork, Banking partners Jason Hollis and Ciaran Herlihy, Employment partner Maura Roe, Tax partners Sonya Manzor and Rachel Fox, Restructuring partner Ruairi Rynn and Anti-Trust partner Cormac Little.

Key Contacts

Myra Garrett Partner

Mark Talbot Partner

Fiachra Cork Senior Associate

Related Practice Areas